AstraZeneca pays hefty price for Chinese weight-loss drug
The drugs giant has licensed an experimental anti-obesity pill from China’s Eccogene as it tries to grab a chunk of the lucrative weight-loss market Key Takeaways: Chinese biotech Eccogene says…
AZN.US
Recent Articles
RELATED ARTICLES
- Jiuyuan Gene seeks IPO cash for bet on weight-loss drugs
-
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
1672.HK
-
Innovent Bio hopes for plus-sized profits from obesity drug
1801.HK
-
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
- InSilico seeks IPO boost to get AI drugs over the line
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs
GRCL.US
Discover hidden China stock gems in our weekly newsletter